These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Clinical relevance of mechanisms of antifungal drug resistance in yeasts. Sanglard D Enferm Infecc Microbiol Clin; 2002 Nov; 20(9):462-9; quiz 470, 479. PubMed ID: 12425880 [TBL] [Abstract][Full Text] [Related]
8. Prevalence rates and antifungal susceptibility profiles of the Candida parapsilosis species complex: results from a nationwide surveillance of candidaemia in Brazil. Gonçalves SS; Amorim CS; Nucci M; Padovan AC; Briones MR; Melo AS; Colombo AL Clin Microbiol Infect; 2010 Jul; 16(7):885-7. PubMed ID: 19686280 [TBL] [Abstract][Full Text] [Related]
9. Cross-Resistance of clinical isolates of Candida albicans and Candida glabrata to over-the-counter azoles used in the treatment of vaginitis. Cross EW; Park S; Perlin DS Microb Drug Resist; 2000; 6(2):155-61. PubMed ID: 10990271 [TBL] [Abstract][Full Text] [Related]
10. Antifungal drug resistance among Candida species: mechanisms and clinical impact. Sanguinetti M; Posteraro B; Lass-Flörl C Mycoses; 2015 Jun; 58 Suppl 2():2-13. PubMed ID: 26033251 [TBL] [Abstract][Full Text] [Related]
11. The effect of antifungal resistance development on the virulence of Candida species. Bohner F; Papp C; Gácser A FEMS Yeast Res; 2022 Apr; 22(1):. PubMed ID: 35325128 [TBL] [Abstract][Full Text] [Related]
12. Azole susceptibility and resistance in Candida dubliniensis. Pinjon E; Moran GP; Coleman DC; Sullivan DJ Biochem Soc Trans; 2005 Nov; 33(Pt 5):1210-4. PubMed ID: 16246083 [TBL] [Abstract][Full Text] [Related]
14. Infections due to resistant Candida species in patients with cancer who are receiving chemotherapy. Wingard JR Clin Infect Dis; 1994 Aug; 19 Suppl 1():S49-53. PubMed ID: 7948571 [TBL] [Abstract][Full Text] [Related]
16. Recent approaches to antifungal therapy for invasive mycoses. Mathew BP; Nath M ChemMedChem; 2009 Mar; 4(3):310-23. PubMed ID: 19170067 [TBL] [Abstract][Full Text] [Related]
17. Antifungals in Clinical Use and the Pipeline. Johnson MD Infect Dis Clin North Am; 2021 Jun; 35(2):341-371. PubMed ID: 34016281 [TBL] [Abstract][Full Text] [Related]
18. In Vitro Activities of Novel Azole Compounds ATTAF-1 and ATTAF-2 against Fluconazole-Susceptible and -Resistant Isolates of Candida Species. Fakhim H; Emami S; Vaezi A; Hashemi SM; Faeli L; Diba K; Dannaoui E; Badali H Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795371 [TBL] [Abstract][Full Text] [Related]
19. Antifungal activities of diphenyl diselenide and ebselen against echinocandin-susceptible and -resistant strains of Candida parapsilosis. Chassot F; Pozzebon Venturini T; Baldissera Piasentin F; Morais Santurio J; Estivalet Svidzinski TI; Hartz Alves S New Microbiol; 2016 Oct; 39(4):301-303. PubMed ID: 27727401 [TBL] [Abstract][Full Text] [Related]
20. Pathogenicity and drug resistance in Candida albicans and other yeast species. A review. Mishra NN; Prasad T; Sharma N; Payasi A; Prasad R; Gupta DK; Singh R Acta Microbiol Immunol Hung; 2007 Sep; 54(3):201-35. PubMed ID: 17896473 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]